Contrasting Achaogen (AKAO) & The Competition
Achaogen (NASDAQ: AKAO) is one of 293 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Achaogen to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, valuation, profitability and earnings.
Institutional & Insider Ownership
84.1% of Achaogen shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 8.4% of Achaogen shares are owned by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Achaogen and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent recommendations and price targets for Achaogen and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Achaogen currently has a consensus price target of $28.00, suggesting a potential upside of 75.55%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 32.05%. Given Achaogen’s stronger consensus rating and higher probable upside, research analysts clearly believe Achaogen is more favorable than its rivals.
Risk and Volatility
Achaogen has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Achaogen’s rivals have a beta of 6.57, meaning that their average share price is 557% more volatile than the S&P 500.
Earnings & Valuation
This table compares Achaogen and its rivals top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Achaogen||$35.51 million||-$68.05 million||-5.05|
|Achaogen Competitors||$473.28 million||$171.89 million||-6.94|
Achaogen’s rivals have higher revenue and earnings than Achaogen. Achaogen is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Achaogen Company Profile
Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company’s Early Development programs include C-Scape and LpxC.
Receive News & Ratings for Achaogen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.